Related Experiment Videos
Expression of cancer testis genes in human brain tumors
U Sahin1, M Koslowski, O Türeci
1Department of Medicine, Saarland University Medical School, Homburg, Germany.
Abstract:
Cancer-testis (CT) genes are expressed in a variety of human cancers but not in normal tissues, except for testis tissue, and represent promising targets for immunotherapeutic and gene therapeutic approaches. Because little is known about their composite expression in human brain tumors, we investigated the expression of seven CT genes (MAGE-3, NY-ESO-1, HOM-MEL-40/SSX-2, SSX-1, SSX-4,HOM-TES-14/SCP-1, and HOM-TES-85) in 88 human brain tumor specimens. Meningiomas expressed only HOM-TES-14/SCP-1 (18% of meningiomas were HOM-TES-14/SCP-1 positive) and did not express any other CT genes. One ependymoma was negative for all CT genes tested. SSX-4 was the only CT gene expressed in oligodendrogliomas (2 of 5 cases), and it was also expressed in oligoastrocytomas (3 of 4 cases) and astrocytomas (10 of 37 cases). Astrocytomas were most frequently positive for HOM-TES-14/SCP-1 (40%) and SSX-4 (27%), followed by HOM-TES-85 (13%), SSX-2 (11%), and MAGE-3 (7%). Whereas MAGE-3 was detected only in grade IV astrocytomas, the expression of the other CT genes showed no clear correlation with histological grade. Of 39 astrocytomas, 60% expressed at least one CT gene, 21% expressed two CT genes, and 8% coexpressed three CT genes of the seven CT genes investigated. We conclude that a majority of oligoastrocytomas and astrocytomas might be amenable to specific immunotherapeutic interventions. However, the identification of additional tu-mor-specific antigens with a frequent expression in gliomas is warranted to allow for the development of widely applicable polyvalent glioma vaccines.
Insights
Cancer-testis genes show promise for brain tumor immunotherapy. Astrocytomas and oligoastrocytomas frequently express these genes, suggesting potential therapeutic targets. Further research is needed for broad glioma vaccine development.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Cancer-testis (CT) genes are expressed in various cancers but not normal tissues (except testes), making them potential therapeutic targets.
- Limited data exists on the expression of CT genes in human brain tumors.
- Seven specific CT genes (MAGE-3, NY-ESO-1, SSX family, HOM-TES-14/SCP-1, HOM-TES-85) were selected for investigation.
Purpose of the Study:
- To investigate the expression profile of seven key Cancer-testis (CT) genes in 88 human brain tumor specimens.
- To determine the potential of these CT genes as targets for immunotherapy in brain tumors.
Main Methods:
- Analysis of seven CT genes (MAGE-3, NY-ESO-1, HOM-MEL-40/SSX-2, SSX-1, SSX-4, HOM-TES-14/SCP-1, HOM-TES-85) expression.
- Studied 88 human brain tumor specimens, including meningiomas, ependymomas, oligodendrogliomas, oligoastrocytomas, and astrocytomas.
- Utilized techniques to detect gene expression in tumor tissues.
Main Results:
- Meningiomas expressed only HOM-TES-14/SCP-1 (18%). Ependymomas showed no CT gene expression.
- SSX-4 was found in oligodendrogliomas (40%), oligoastrocytomas (75%), and astrocytomas (27%).
- Astrocytomas frequently expressed HOM-TES-14/SCP-1 (40%) and SSX-4 (27%). 60% of astrocytomas expressed at least one CT gene, with some co-expressing multiple genes. MAGE-3 was restricted to grade IV astrocytomas.
Conclusions:
- A significant proportion of astrocytomas and oligoastrocytomas express CT genes, indicating potential for targeted immunotherapies.
- HOM-TES-14/SCP-1 and SSX-4 are frequently expressed in certain glioma subtypes.
- Development of widely applicable polyvalent glioma vaccines requires identification of additional tumor-specific antigens with frequent expression.